13.80 -0.11 (-0.81%)
After hours: 4:11PM EDT
|Bid||13.12 x 900|
|Ask||14.88 x 3000|
|Day's Range||13.41 - 14.03|
|52 Week Range||4.65 - 14.90|
|Beta (3Y Monthly)||1.54|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 1, 2019 - May 6, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.60|
Fluidigm Corp creates, manufactures, and markets technologies and life-science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon microfluidics and mass cytometry technologies. Fluidigm Corp had annual average EBITDA growth of 19.90% over the past ten years. Warning! GuruFocus has detected 7 Warning Signs with FLDM.
A caller during the Lightning Round of "Mad Money" Monday asked Jim Cramer about Fluidigm Corp. Let's check out the charts of Fluidigm, which makes microfluidic systems for the life science and agricultural biotechnology industries. In this daily bar chart of FLDM, below, we can see that prices have rallied nicely from the middle of June.
Fluidigm Corporation (FLDM) today announced that Colin McCracken has joined the company as its Chief Commercial Officer. McCracken will be responsible for leading all commercial activities, driving revenue growth in new and existing markets and expanding the company’s global reach. As a member of the executive leadership team reporting to President and CEO Chris Linthwaite, McCracken will advance Fluidigm’s commercialization infrastructure and organization toward further market adoption of the company’s products, particularly in the growing scientific community studying the human immune system.
SOUTH SAN FRANCISCO, Calif., Feb. 22, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive.
NEW YORK, Feb. 19, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Fluidigm Corporation (FLDM) today announced that the Compensation Committee of its Board of Directors, which is composed entirely of independent directors, granted equity awards effective as of February 12, 2019, under Fluidigm’s 2017 Inducement Award Plan (Plan), as a material inducement to seven individuals entering into employment with Fluidigm. In connection with the individuals entering into employment with Fluidigm as new employees, none of whom were previously employees or directors of Fluidigm, the individuals received awards totaling an aggregate of 48,900 restricted stock units (RSU Awards).
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! In December 2018, Fluidigm Corporation (NASDAQ:FLDM) announcedRead More...
Fluidigm (FLDM) delivered earnings and revenue surprises of 70.00% and 5.80%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
The South San Francisco, California-based company said it had a loss of 36 cents per share. Losses, adjusted for one-time gains and costs, were 6 cents per share. The company that makes equipment to control ...
Fourth quarter revenue increased 17 percent to $32.3 million Mass cytometry revenue growth of 48 percent in fourth quarter Full year 2018 revenue increased 11 percent to.
SOUTH SAN FRANCISCO, Calif., Feb. 07, 2019 -- Fluidigm Corporation (NASDAQ: FLDM) and Indica Labs, Inc., today announced a co-marketing relationship for scalable and.
Fluidigm Corporation (FLDM) today announced it is one of 11 partners in the TIMID Consortium, a unique effort of six academic institutions and five life science and pharma companies that utilizes both mass cytometry and Imaging Mass Cytometry™ along with other technologies to explore the common cellular basis of T cell-driven immune-mediated inflammatory diseases (IMIDs). The research will potentially empower more precise treatments using existing drugs and identify new targets for future drug development.
SOUTH SAN FRANCISCO, Calif., Jan. 31, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, today announced the introduction of.
NEW YORK, Jan. 24, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
SOUTH SAN FRANCISCO, Calif., Jan. 14, 2019 -- Fluidigm Corporation (NASDAQ:FLDM), a leader in mass cytometry and microfluidics technologies, announced today that it will report.
SOUTH SAN FRANCISCO, Calif. and MONTREAL, Jan. 08, 2019 -- Caprion Biosciences, a world-leading specialty contract research organization (CRO) laboratory providing.
Does Fluidigm Corporation (NASDAQ:FLDM) represent a good buying opportunity at the moment? Let’s briefly check the hedge fund interest towards the company. Hedge fund firms constantly search out bright intellectuals and highly-experienced employees and throw away millions of dollars on research activities, so it is no wonder why they tend to generate millions in profits […]